Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices and erectile dysfunction Diagnostics Deliver Drugs and Profits

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 29 July 2015 17:13
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis.
Read more...
 

Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester of Bell Potter Securities

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 22 July 2015 15:22
Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.
Read more...
 

Four Small-Cap Medtechs Primed for Outsize Returns: Zacks' Brian Marckx

Print E-mail
By Staff of The Life Sciences Report   
Wednesday, 15 July 2015 14:46
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement.
Read more...
 

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 24 June 2015 14:45
Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners.
Read more...
 

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 17 June 2015 18:06
The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies.
Read more...
 

The Big Picture: Edison's Pooya Hemami Looks Beyond Cancer for Biotech Winners

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 10 June 2015 19:16
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health.   
Read more...
 

An Undervalued Biotech Is Testing the Cure for Cancer Now, and Chen Lin Wants In

Print E-mail
By William Kent   
Wednesday, 03 June 2015 12:57
Chen Lin produces a monthly scorecard that tracks the performance of the stocks in which he invests. Every month, he reveals how he is doing in his newsletter, What Is Chen Buying? What is Chen Selling? 
Read more...
 

As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 27 May 2015 18:43
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts.
Read more...
 

Exceptional Management and Disruptive Products Top the Investment Checklist for Vista Partners' Ross Silver

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 20 May 2015 15:16
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.  
Read more...
 

Fire Up the Immune System to Fight Cancers and Boost Portfolios: John McCamant

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 13 May 2015 18:23
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 51

Newsletter

BioMedReports Novavax Reports positive data from Phase 2 Trial of Quadrivalent Seasonal Influenza VLP: Clinical stage vacci... http://t.co/NwVdI7NZtn
2hreplyretweetfavorite
BioMedReports Pfizer Pulls The Plug On OTC Lipitor And It's The Patients' Fault... http://t.co/XIW9hJ4aXN
18hreplyretweetfavorite
BioMedReports Viking Therapeutics Reports Will Conduct Phase 2 Trial of VK2809; Mylan Receives Unconditional Clearance from ... http://t.co/mCjvLeVWaw
18hreplyretweetfavorite